Clinical TrialJun 23, 2026, 08:31 AM
Quantum BioPharma's Lucid-MS Drug Enters Phase 2 Trials
AI Summary
Quantum BioPharma Ltd. announced that its patented, first-in-class drug candidate, Lucid-MS, is preparing to enter Phase 2 clinical trials for Multiple Sclerosis. Lucid-MS takes a novel approach by directly targeting the myelin sheath, which is destroyed by MS, and has shown to prevent and reverse myelin degradation in preclinical models. This development was featured in an editorial by BioMedWire, highlighting the potential to address a significant unmet medical need. Additionally, Quantum BioPharma holds a 19.84% stake in Unbuzzd Wellness Inc. and receives royalty payments from sales of UNBUZZD(TM).
Key Highlights
- Quantum BioPharma's Lucid-MS drug candidate is preparing to enter Phase 2 clinical trials.
- Lucid-MS is a patented, first-in-class drug targeting myelin degradation in Multiple Sclerosis.
- The company's progress was highlighted in an editorial published by BioMedWire.
- Quantum BioPharma retains 19.84% ownership in Unbuzzd Wellness Inc. as of March 31, 2026.
- The company receives 7% royalty on Unbuzzd sales until payments total $250 million, then 3% perpetually.
- Quantum retains 100% rights for pharmaceutical and medical uses of UNBUZZD(TM).
Price Impact
More from QNTM